1990;113:104 10. 43. Bhandari AK, Anderson JL, Gilbert EM, et al. Correlation of symp- toms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group. Am Heart J. 1992;124:381 6. 44. Sintetos AL, Roark SF, Smith MS, et al. Incidence of symptomatic tachy- cardia in untreated patients with paroxysmal supraventricular tachycardia. Arch Intern Med. 1986;146:2205 9. 45. Henthorn RW, Waldo AL, Anderson JL, et al. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. Circulation. 1991;83:119 25. 46. Dorian P, Naccarelli GV, Coumel P, et al. A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachy- cardia. The Flecainide Multicenter Investigators Group. Am J Cardiol. 1996;77:89A 95A. 47. Lu C-W, Wu M-H, Chen H-C, et al. Epidemiological profile of Wolff- Parkinson-White syndrome in a general population younger than 50 years of age in an era of radiofrequency catheter ablation. Int J Cardiol. 2014;174:530 4. 48. Whinnett ZI, Sohaib SMA, Davies DW. Diagnosis and management of supraventricular tachycardia. BMJ. 2012;345:e7769. 49. Porter MJ, Morton JB, Denman R, et al. Influence of age and gender on the mechanism of supraventricular tachycardia. Heart Rhythm. 2004;1:393 6. 50. Campbell RW. Supraventricular tachycardia: occasional nuisance or fre- quent threat? Eur Heart J. 1996; 17 Suppl C:21 5. 51. Cairns CB, Niemann JT. Intravenous adenosine in the emergency depart- ment management of paroxysmal supraventricular tachycardia. Ann Emerg Med. 1991;20:717 21. 52. Goyal R, Zivin A, Souza J, et al. Comparison of the ages of tachy- cardia onset in patients with atrioventricular nodal reentrant tachy- cardia and accessory pathway-mediated tachycardia. Am Heart J. 1996;132:765 7. 53. Maryniak A, Bielawska A, Bieganowska K, et al. 